Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Science, Tehran 1411713135, Iran.
Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan 65178-38678, Iran.
Future Microbiol. 2020 Dec;15:1747-1758. doi: 10.2217/fmb-2020-0120. Epub 2021 Jan 6.
COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients.
由 SARS-CoV-2 引起的 COVID-19 是一个国际关注的问题。这种感染需要紧急努力开发新的抗病毒化合物。迄今为止，尚未确定用于控制这种疾病的特定药物。开发新的治疗方法通常需要很长时间，因此使用重新利用广谱抗病毒药物可能是立即应对的有效策略。在这篇综述中，评估了一些具有潜在疗效的广谱抗病毒药物，这些药物通过靶向病毒刺突蛋白 (S 蛋白)、RNA 依赖性 RNA 聚合酶 (RdRp)、3-糜蛋白酶样蛋白酶 (3CLpro) 和木瓜蛋白酶样蛋白酶 (PLpro) 抑制病毒复制，这些在冠状病毒的发病机制和生命周期中至关重要，被评估为 COVID-19 患者对抗 SARS-CoV-2 的可能治疗选择。
